Find Funding Opportunities

The National Institute of Neurological Disorders and Stroke (NINDS) invites new and renewal applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic basic, translational and clinical research programs while serving as local resources and national leaders in PD research. The overall theme, proposed research projects, and associated cores must inform the etiology, pathogenesis or treatment of PD. Investigations on related parkinsonian disorders may be included, to the extent that these directly inform research on PD. Required components include: 1) a minimum of three interdisciplinary research projects, with at least one translational research project focusing on the development of therapeutics, diagnostics, or clinical criteria that would ultimately lead to new approaches for the treatment of PD; 2) Research Cores that are essential to accomplish the aims of proposed research projects, plus an Administrative Core; and 3) a specific plan to provide for training of PD researchers. Because basic research serves as the foundation for discovery in the Udall Centers program, NINDS programmatic priorities will focus on applications that propose multidisciplinary programs including a well-integrated basic research project. A considerable degree of synergy must be evident among Center research projects and Cores, such that successful completion of the aims could not be accomplished without the Center structure.

The goal of this funding opportunity announcement (FOA) is to support preclinical development and testing of new therapies for neurological disorders. The program will facilitate therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. Projects should include therapeutic leads, a strong biological rationale for the intended approach, and where available in vivo proof-of-concept of efficacy. The program supports preclinical optimization and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND), Investigational Device Exemption (IDE), 510(k), or 510(k) de novo application to the Food and Drug Administration (FDA) can be submitted during the project period. The program can also support Phase 0 clinical trials for small molecule drugs, proof-of-concept for biologics, or proof-of-concept/pilot clinical trials for therapeutic devices. The program does not support early-stage therapeutic discovery activities such as screening. The program also excludes clinical research, other than those specified above, basic research, and studies of disease mechanism or mechanistic/mechanism of action studies of the intended therapeutic. The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. This is a milestone-driven cooperative agreement program involving participation of NINDS program staff in the development of the project plan and monitoring of research progress.

The goal of this Funding Opportunity Announcement (FOA) is to support any research activities required to advance candidate therapeutics through Investigational New Drug (IND), Investigational Device Exemption (IDE), or 510(K) submission to the Food and Drug Administration (FDA), and ready them for clinical testing for neurological disorders. Projects should include a strong biological rationale for the intended approach, supporting data from rigorously designed experiments, and proposed studies that exhibit methodological rigor. Such projects, if successful, should lead directly to or support another project (e.g. cooperative agreement in translational research) that will include all remaining activities for submission of an IND, IDE, or 510(k) application to the FDA. The scope includes only preclinical development activities for therapeutic drugs, devices, and biologics; development of diagnostics or rehabilitation strategies cannot be supported. Clinical research, basic research, and studies of disease mechanism are outside the program scope.

The goal of this Funding Opportunity Announcement (FOA) is to provide support for investigators to develop new drugs for the prevention or treatment of Alzheimers disease (AD). Specifically, this initiative is aimed at researchers who have promising small molecule compounds but lack outside drug development expertise and infrastructure support to advance these compounds to the clinic. This Alzheimers Disease Therapeutics Program adjunct to the NIH Blueprint Neurotherapeutics Program will allow investigators access to a virtual pharma network of contract research organizations, technical and regulatory experts and project managers, with extensive biopharma-industry experience. The long-term goal of the Alzheimers Disease Therapeutics Program is to advance projects from medicinal chemistry optimization through Phase l clinical trials and facilitate industry partnership for their further development.

The National Institute on Aging (NIA) working in part with funds contributed by the John A. Hartford Foundation (http://www.jhartfound.org/) and The American Federation for Aging Research (http://afar.org/), are pursuing this initiative to encourage and assist the development of future leaders in the field of aging by supporting clinically trained (primarily physician) faculty members early in their careers to gain additional research training and to establish independent programs in aging research.

The National Institute on Aging (NIA),working in part with funds contributed by the John A. Hartford Foundation (http://www.jhartfound.org/)and The American Federation for Aging Research (http://afar.org/), are pursuing this initiative to encourage and assist the development of future leaders in the field of aging by supporting clinically trained (primarily physician) faculty members early in their careers to gain additional research training and to establish independent programs in aging research.

This Funding Opportunity Announcement (FOA) encourages applications for exploratory/developmental translational research on therapeutics for reducing mortality and morbidity caused by acute exposures to chemical threat agents. Chemical threats include chemical warfare nerve agents such as sarin and VX, toxic industrial chemicals such as cyanide and phosgene, and toxic agricultural chemicals such as parathion and sodium fluoroacetate. Projects supported by this FOA are expected to generate preliminary preclinical, screening and efficacy data that would enable the development of competitive applications for more extensive support from the NIH CounterACT program (see www.ninds.nih.gov/counteract for a description) and other related translational research programs.

This funding opportunity announcement (FOA), through an open competition, solicits applications for Centers for Collaborative Research in Fragile X. Successful Centers will be composed of transdisciplinary teams of investigators working together to address specific scientific questions within targeted areas of research. The targeted areas of research are intended to address research gaps, drive discovery and further develop research relevant to Fragile X syndrome and (Fragile X Gene) (FMR1) Related Conditions.

The National Cancer Institute (NCI), the National Institute of Dental and Craniofacial Research (NIDCR), and the National Institute of Neurological Disorders and Stroke (NINDS), at the National Institutes of Health (NIH), invite applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund 5-year P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resource core facilities (cores), improved research model systems, and collaborative research projects with other institutions. The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the 5 year term of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Development Program to foster careers in organ-based translational science.

The purpose of this FOA is to encourage Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.